The REDEFINE 1 trial found that when evaluating the treatment effect regardless of whether patients stayed on treatment, those treated with CagriSema achieved weight loss of 20.4% (from an average baseline body weight of 236 lb) at 68 weeks versus 3.0% (from an average baseline body weight of 235 lb) for the placebo group which was statistically significant
The platform provides ongoing updates on regulatory changes, new medication approvals, and coverage policy shifts that affect who can access GLP-1 therapy
However, regulations around compounding are actively changing the FDA removed semaglutide from its shortage list in 2024, which affects what compounding pharmacies can legally produce
Getting peoples diabetes under better control, which these medications are very effective for, makes them overall healthier, and reduces their overall cardiovascular and cardiometabolic risks
"Three SNPs in the GSTO1, GSTO2 and PRSS11 genes on chromosome 10 are not associated with age-at-onset of Alzheimer's disease"